<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907153</url>
  </required_header>
  <id_info>
    <org_study_id>29714</org_study_id>
    <nct_id>NCT00907153</nct_id>
  </id_info>
  <brief_title>Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vitamin D will improve insulin resistance,
      inflammation, and overall well-being in women with PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As many cells throughout the body possess the vitamin D receptor, adequate vitamin D levels
      may be essential for multiple physiologic functions. In recent years, vitamin D insufficiency
      has been linked to insulin resistance, inflammation, poor psychological health, obesity, type
      2 diabetes, and cardiovascular disease - these are also commonly found in women with
      Polycystic Ovary syndrome (PCOS). We believe that vitamin D insufficiency contributes to
      insulin resistance, inflammation, and psychological distress in women with PCOS. These
      adverse effects may ultimately increase the risk for serious long-term complications in PCOS,
      including type 2 diabetes and cardiovascular disease. The key objectives of this research
      study are to determine the effects of vitamin D supplementation on insulin resistance,
      inflammation, mood and overall well-being in women with PCOS.

      The protocol has been modified by adding the following specific aim: To compare vascular
      function in healthy age and BMI similar matched women to PCOS women pre-treatment. Our
      hypothesis is that PCOS women will have greater attenuations in retinal vascular reactivity
      compared to healthy control women, demonstrating poorer endothelial function. We are
      currently recruiting healthy women who are age and BMI similar to the PCOS women and measure
      their retinal vascular reactivity for comparisons to the PCOS women's pre-treatment vascular
      reactivity. These healthy women will only have a baseline visit in which retinal vascular
      reactivity will be measured. They will not be enrolled in the placebo or Vitamin D
      randomization process as described above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Quantitative insulin sensitivity check index (QUICKI) is a validated measure of insulin sensitivity based on fasting insulin and glucose. Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean High Sensitive C-reactive Protein (hsCRP)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>High sensitive C-reactive protein (hsCRP) was assessed as a measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Systolic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Diastolic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Fasting Glucose</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Glucose was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Fasting Insulin</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Insulin was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 2-hour Glucose</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 2-hour Insulin</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Insulin Sensitivity Index (ISI 0,120)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120). The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated measure of insulin resistance based on fasting insulin and glucose. HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Total Cholesterol</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Lipid profile was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean HDL Cholesterol</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Lipid profile was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean LDL Cholesterol</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Lipid profile was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Triglycerides</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Lipid profile was assessed after 12 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Total Testosterone</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Free Testosterone</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean 25-hydroxyvitamin D</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Total 25-hydroxyvitamin D was assayed by the Immunodiagnostic Systems radioimmunoassay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Vitamin D Binding Protein</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Vitamin D binding protein levels were assessed as it has been linked with insulin resistance and type 2 diabetes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Intact Parathyroid Hormone (i-PTH)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Intact parathyroid hormone levels were assessed as they have been linked with obesity and insulin resistance.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PCOS based on:

               -  Eight or fewer menstrual periods per year or spontaneous intermenstrual periods
                  of greater than or equal to 45 days, and

               -  Elevated testosterone levels

        Exclusion Criteria:

          -  Current Pregnancy or Nursing

          -  Elevated calcium

          -  Kidney Stones or kidney disease

          -  Current use of vitamin D (other than a multivitamin)

          -  Use of metformin or other insulin sensitizing drugs in the last 3 months

          -  Elevated prolactin or untreated thyroid disease

          -  Diabetes, Liver disease, Heart disease, or other serious medical condition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nazia Raja-Khan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Raja-Khan N, Shah J, Stetter CM, Lott ME, Kunselman AR, Dodson WC, Legro RS. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014 Jun;101(6):1740-6. doi: 10.1016/j.fertnstert.2014.02.021. Epub 2014 Mar 14.</citation>
    <PMID>24636395</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>November 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Nazia Raja-Khan</investigator_full_name>
    <investigator_title>M.D., Assistant Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 patients were screened for eligibility between July 2009 and November 2010 at Medicine and Obstetrics and Gynecology clinics at an academic medical center in Hershey, PA.</recruitment_details>
      <pre_assignment_details>28 of 36 participants were randomized. Of those not randomized, 3 did not meet inclusion criteria, 3 declined to participate, and 2 were not randomized for other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="5.2"/>
                    <measurement group_id="B2" value="28.7" spread="5.6"/>
                    <measurement group_id="B3" value="28.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.20" spread="4.53"/>
                    <measurement group_id="B2" value="35.09" spread="9.81"/>
                    <measurement group_id="B3" value="36.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.46" spread="10.00"/>
                    <measurement group_id="B2" value="113.91" spread="10.21"/>
                    <measurement group_id="B3" value="115.56" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mm hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.08" spread="8.28"/>
                    <measurement group_id="B2" value="74.88" spread="7.72"/>
                    <measurement group_id="B3" value="76.83" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-hydroxyvitamin D</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.95" spread="9.47"/>
                    <measurement group_id="B2" value="22.20" spread="6.86"/>
                    <measurement group_id="B3" value="21.15" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D binding protein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.46" spread="8.53"/>
                    <measurement group_id="B2" value="31.95" spread="7.54"/>
                    <measurement group_id="B3" value="31.34" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intact parathyroid hormone (i-PTH)</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.81" spread="27.34"/>
                    <measurement group_id="B2" value="33.17" spread="17.73"/>
                    <measurement group_id="B3" value="36.72" spread="22.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.92" spread="9.46"/>
                    <measurement group_id="B2" value="83.73" spread="9.33"/>
                    <measurement group_id="B3" value="84.29" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting insulin</title>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.31" spread="9.60"/>
                    <measurement group_id="B2" value="27.13" spread="15.79"/>
                    <measurement group_id="B3" value="26.75" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.08" spread="36.29"/>
                    <measurement group_id="B2" value="110.07" spread="23.68"/>
                    <measurement group_id="B3" value="115.64" spread="30.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour insulin</title>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214.69" spread="146.41"/>
                    <measurement group_id="B2" value="107.07" spread="55.20"/>
                    <measurement group_id="B3" value="157.04" spread="118.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity index 0,120</title>
          <description>Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120). The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).</description>
          <units>mg·l^2/mmol·mU·min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.55" spread="23.26"/>
                    <measurement group_id="B2" value="63.56" spread="16.37"/>
                    <measurement group_id="B3" value="59.84" spread="19.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>The primary outcome was quantitative insulin sensitivity check index (QUICKI), a validated measure of insulin sensitivity based on fasting insulin and glucose. Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.302" spread="0.014"/>
                    <measurement group_id="B2" value="0.307" spread="0.029"/>
                    <measurement group_id="B3" value="0.305" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.47" spread="1.82"/>
                    <measurement group_id="B2" value="5.80" spread="3.90"/>
                    <measurement group_id="B3" value="5.65" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.00" spread="42.70"/>
                    <measurement group_id="B2" value="184.27" spread="32.52"/>
                    <measurement group_id="B3" value="178.57" spread="37.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.54" spread="17.60"/>
                    <measurement group_id="B2" value="37.00" spread="10.83"/>
                    <measurement group_id="B3" value="40.96" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.62" spread="36.96"/>
                    <measurement group_id="B2" value="117.33" spread="28.56"/>
                    <measurement group_id="B3" value="108.64" spread="33.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyecrides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.08" spread="71.61"/>
                    <measurement group_id="B2" value="149.47" spread="85.46"/>
                    <measurement group_id="B3" value="144.64" spread="78.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High sensitive C-reactive protein (hsCRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.95" spread="5.24"/>
                    <measurement group_id="B2" value="4.42" spread="4.34"/>
                    <measurement group_id="B3" value="6.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.23" spread="28.16"/>
                    <measurement group_id="B2" value="41.27" spread="17.29"/>
                    <measurement group_id="B3" value="48.48" spread="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.08" spread="15.79"/>
                    <measurement group_id="B2" value="14.00" spread="10.88"/>
                    <measurement group_id="B3" value="16.89" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>Quantitative insulin sensitivity check index (QUICKI) is a validated measure of insulin sensitivity based on fasting insulin and glucose. Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>Quantitative insulin sensitivity check index (QUICKI) is a validated measure of insulin sensitivity based on fasting insulin and glucose. Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" lower_limit="-0.020" upper_limit="0.004"/>
                    <measurement group_id="O2" value="0.009" lower_limit="-0.003" upper_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>-0.000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean High Sensitive C-reactive Protein (hsCRP)</title>
        <description>High sensitive C-reactive protein (hsCRP) was assessed as a measure of inflammation.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean High Sensitive C-reactive Protein (hsCRP)</title>
          <description>High sensitive C-reactive protein (hsCRP) was assessed as a measure of inflammation.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="-2.46" upper_limit="4.27"/>
                    <measurement group_id="O2" value="2.04" lower_limit="-1.37" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.89</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Systolic Blood Pressure</title>
        <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Systolic Blood Pressure</title>
          <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="-7.13" upper_limit="8.42"/>
                    <measurement group_id="O2" value="4.29" lower_limit="-3.15" upper_limit="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.32</ci_lower_limit>
            <ci_upper_limit>7.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Diastolic Blood Pressure</title>
        <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Diastolic Blood Pressure</title>
          <description>Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-4.96" upper_limit="3.14"/>
                    <measurement group_id="O2" value="5.60" lower_limit="1.69" upper_limit="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.07</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Fasting Glucose</title>
        <description>Glucose was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Fasting Glucose</title>
          <description>Glucose was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-7.96" upper_limit="6.56"/>
                    <measurement group_id="O2" value="-6.98" lower_limit="-14.31" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.97</ci_lower_limit>
            <ci_upper_limit>16.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Fasting Insulin</title>
        <description>Insulin was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Fasting Insulin</title>
          <description>Insulin was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.04" lower_limit="-3.96" upper_limit="30.05"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-18.03" upper_limit="16.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-210.29</ci_lower_limit>
            <ci_upper_limit>37.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 2-hour Glucose</title>
        <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 2-hour Glucose</title>
          <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.66" lower_limit="-33.22" upper_limit="9.89"/>
                    <measurement group_id="O2" value="1.14" lower_limit="-20.10" upper_limit="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.94</ci_lower_limit>
            <ci_upper_limit>17.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 2-hour Insulin</title>
        <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 2-hour Insulin</title>
          <description>Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.02" lower_limit="-124.5" upper_limit="0.49"/>
                    <measurement group_id="O2" value="13.06" lower_limit="-47.94" upper_limit="74.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-75.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-161.9</ci_lower_limit>
            <ci_upper_limit>11.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Insulin Sensitivity Index (ISI 0,120)</title>
        <description>Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120). The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Insulin Sensitivity Index (ISI 0,120)</title>
          <description>Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120). The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg·l^2/mmol·mU·min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" lower_limit="-16.87" upper_limit="30.21"/>
                    <measurement group_id="O2" value="5.94" lower_limit="-17.77" upper_limit="29.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.59</ci_lower_limit>
            <ci_upper_limit>34.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated measure of insulin resistance based on fasting insulin and glucose. HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated measure of insulin resistance based on fasting insulin and glucose. HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="-0.90" upper_limit="6.03"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-4.01" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>7.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Total Cholesterol</title>
        <description>Lipid profile was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Total Cholesterol</title>
          <description>Lipid profile was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" lower_limit="-19.04" upper_limit="15.66"/>
                    <measurement group_id="O2" value="-1.80" lower_limit="-19.55" upper_limit="15.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.43</ci_lower_limit>
            <ci_upper_limit>24.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean HDL Cholesterol</title>
        <description>Lipid profile was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean HDL Cholesterol</title>
          <description>Lipid profile was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-6.52" upper_limit="5.12"/>
                    <measurement group_id="O2" value="1.23" lower_limit="-4.68" upper_limit="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.12</ci_lower_limit>
            <ci_upper_limit>6.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean LDL Cholesterol</title>
        <description>Lipid profile was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean LDL Cholesterol</title>
          <description>Lipid profile was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" lower_limit="-14.70" upper_limit="14.46"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-15.24" upper_limit="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.29</ci_lower_limit>
            <ci_upper_limit>20.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Triglycerides</title>
        <description>Lipid profile was assessed after 12 hours of fasting.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Triglycerides</title>
          <description>Lipid profile was assessed after 12 hours of fasting.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" lower_limit="-34.11" upper_limit="29.69"/>
                    <measurement group_id="O2" value="-12.44" lower_limit="-44.68" upper_limit="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.61</ci_lower_limit>
            <ci_upper_limit>55.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Total Testosterone</title>
        <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Total Testosterone</title>
          <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="-8.05" upper_limit="14.06"/>
                    <measurement group_id="O2" value="10.16" lower_limit="-1.16" upper_limit="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.81</ci_lower_limit>
            <ci_upper_limit>8.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Free Testosterone</title>
        <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Free Testosterone</title>
          <description>Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="-1.29" upper_limit="6.63"/>
                    <measurement group_id="O2" value="5.82" lower_limit="1.82" upper_limit="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.70</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean 25-hydroxyvitamin D</title>
        <description>Total 25-hydroxyvitamin D was assayed by the Immunodiagnostic Systems radioimmunoassay.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 25-hydroxyvitamin D</title>
          <description>Total 25-hydroxyvitamin D was assayed by the Immunodiagnostic Systems radioimmunoassay.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.63" lower_limit="33.50" upper_limit="57.76"/>
                    <measurement group_id="O2" value="1.32" lower_limit="-10.93" upper_limit="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>44.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.13</ci_lower_limit>
            <ci_upper_limit>61.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Vitamin D Binding Protein</title>
        <description>Vitamin D binding protein levels were assessed as it has been linked with insulin resistance and type 2 diabetes.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Vitamin D Binding Protein</title>
          <description>Vitamin D binding protein levels were assessed as it has been linked with insulin resistance and type 2 diabetes.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="-1.60" upper_limit="3.62"/>
                    <measurement group_id="O2" value="-0.55" lower_limit="-3.14" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.08</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Intact Parathyroid Hormone (i-PTH)</title>
        <description>Intact parathyroid hormone levels were assessed as they have been linked with obesity and insulin resistance.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Intact Parathyroid Hormone (i-PTH)</title>
          <description>Intact parathyroid hormone levels were assessed as they have been linked with obesity and insulin resistance.</description>
          <population>All analyses were by intention to treat. All randomized participants received and ingested the treatment that they were randomly assigned to.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.28" lower_limit="-39.80" upper_limit="-8.76"/>
                    <measurement group_id="O2" value="-16.45" lower_limit="-31.40" upper_limit="-1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model-based differences adjusted for oral contraceptive use and season.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.34</ci_lower_limit>
            <ci_upper_limit>13.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Twelve weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>Vitamin D: Vitamin D 300 mcg by mouth once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo by mouth once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nazia Raja-Khan</name_or_title>
      <organization>Penn State Hershey Medical Center</organization>
      <phone>717-531-8395</phone>
      <email>nrajakhan@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

